Key result
Doubase C eliminates QTc prolongation >500 ms vs hydroxychloroquine-azithromycin in mild to moderate COVID-19.
Why the study?
Few studies in the Democratic Republic of the Congo have assessed the safety of Hydroxychloroquine-azithromycin and new COVID-19 treatments like Doubase C regarding QTc prolongation.
Does Doubase C compared to hydroxychloroquine-azithromycin reduce the incidence of QTc prolongation in patients with mild to moderate COVID-19?
RCT (n=261)
Randomization table
No
Does Doubase C compared to hydroxychloroquine-azithromycin reduce the incidence of QTc prolongation in patients with mild to moderate COVID-19?
In patients with mild to moderate COVID-19, treatment with Doubase C avoids the risk of QTc prolongation associated with hydroxychloroquine-azithromycin therapy.
Answers are grounded in this paper and cite their sources.
Low QTc prolongation risk with HCQ-AZT (no TdP) in low-comorbidity Congolese patients may support local use; leaves open generalizability and need for larger trials.
Background: QTc prolongation has been described in COVID-19 patients treated with Hydroxychloroquine (HCQ) and Azithromycin (AZT) in western countries. In the Democratic Republic of the Congo (DRC), few studies have assessed the safety of these molecules, and neither have they for new molecules proposed for COVID-19 treatment, such as Doubase C. This study aimed to determine the incidence of QTc prolongation in COVID-19 patients treated with HCQ-AZT or Doubase C. Methods: This study was part of a randomized clinical trial. Data were collected from May 20, 2021, to January 15, 2022. Patients were randomized into two arms; one was treated with Doubase C and the other with HCQ-AZT at standard dosages. Only patients with mild to moderate COVID-19 were included. Results: A total of 261 patients were included. At inclusion, the two groups were comparable (52.5% men, 47.5% women, mean age 41±15 years. The incidence of prolonged QTc interval was 1.5% in the whole group (3.3% on the HCQ-AZT arm and 0% on the Doubase C arm). No ventricular arrhythmias or torsade de pointes, or cardiac arrest were observed. Conclusion: Unlike Doubase C, the HCQ-AZT strategy has a risk of QTc prolongation.
No takes yet. Share an insight, caveat, or question.
Madioko et al. (2022) conducted an RCT in COVID-19 (n=261). Hydroxychloroquine-azithromycin (HCQ-AZT) vs. Doubase C was evaluated on Incidence of prolonged QTc interval (>500 ms). Treatment with hydroxychloroquine and azithromycin resulted in a 3.3% incidence of QTc prolongation >500 ms compared to 0% with Doubase C in patients with mild to moderate COVID-19.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: